(Q40611574)

22 September 2017

title

Chemosensitisation of malignant melanoma by BCL2 antisense therapy (English)

1 reference

22 September 2017

1

B Jansen

1 reference

22 September 2017

V Wacheck

2

1 reference

22 September 2017

E Heere-Ress

3

1 reference

22 September 2017

H Schlagbauer-Wadl

4

1 reference

22 September 2017

C Hoeller

5

1 reference

22 September 2017

T Lucas

6

1 reference

22 September 2017

M Hoermann

7

1 reference

22 September 2017

U Hollenstein

8

1 reference

22 September 2017

K Wolff

9

1 reference

22 September 2017

H Pehamberger

10

1 reference

22 September 2017

language of work or name

English

0 references

publication date

1 November 2000

1 reference

22 September 2017

1 reference

22 September 2017

volume

356

1 reference

22 September 2017

issue

9243

1 reference

22 September 2017

page(s)

1728-1733

1 reference

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903207-4

7 January 2021

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903207-4

7 January 2021

bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903207-4

7 January 2021

Dysregulation of apoptosis in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903207-4

7 January 2021

Bcl-2 expression in malignant melanoma and its prognostic significance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903207-4

7 January 2021

Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903207-4

7 January 2021

BCL-2 antisense therapy in patients with non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903207-4

7 January 2021

Determination of antisense phosphorothioate oligonucleotides and catabolites in biological fluids and tissue extracts using anion-exchange high-performance liquid chromatography and capillary gel electrophoresis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903207-4

7 January 2021

bcl-2 Protein Expression in Cutaneous Malignant Melanoma and Benign Melanocytic Nevi

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903207-4

7 January 2021

BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903207-4

7 January 2021

Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903207-4

7 January 2021

Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903207-4

7 January 2021

Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903207-4

7 January 2021

Prognostic factors for survival of patients treated systemically for disseminated melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903207-4

7 January 2021

Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Gr

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903207-4

7 January 2021

10.1016/S0140-6736(00)03207-4

Identifiers

DOI

1 reference

22 September 2017

1 reference